Monday, August 10, 2009

NNVC - News

NanoViricides, Inc. Anti-Herpes Drug Candidate Reduces Viral Load by 99.99%

Press Release
Source: NanoViricides, Inc.
On Monday August 10, 2009, 7:00 am EDT


WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the herpes simplex viral load was reduced by 99.99% or 10,000 fold in in-vitro studies by nanoviricides(TM) drug candidates. The studies were performed by Thevac in Baton Rouge, LA, in collaboration with the Division of Biotechnology and Molecular Medicine at the LSU School of Veterinary Medicine under the supervision of Dr. Gus Kousoulas.

Four different nanoviricides showed greater than 10,000-fold (>99.99%) reduction in virus quantity compared to untreated controls in a cell culture assay employing the LSU proprietary green-fluorescent-protein-tagged (GFP) modified HSV-1 McKrae strain.

These nanoviricide drug candidates are designed to act against all herpes simplex virus strains, including HSV-1 and HSV-2. The Company has commissioned additional in vitro studies to confirm the results. Animal studies have also been scheduled.

"We are very excited with this success against HSV-1," said Eugene Seymour, MD, MPH, CEO of the Company, adding "and expect this to lead to a topical skin cream against herpes cold sores and genital herpes. This opens up another significant commercial opportunity for the Company."

Herpes simplex virus (HSV) causes "cold sores", the incidence of which is second only to the common cold (100 million recurrences annually in the US alone). In addition, genital herpes prevalence is 67 million infected individuals in the US alone. HSV also causes keratitis, a disease of the eye (250,000 US cases/year).

Existing therapies include acyclovir and drugs chemically related to it. These drugs, nucleoside analogs, act by inhibiting viral DNA synthesis. However, there is known drug toxicity due to interference with human metabolism. Currently, there is no cure for herpes infection.

Nanoviricides act by a novel and distinctly different mechanism compared to existing drugs. Nanoviricides are designed to mimic the human cell surface to which the virus binds. Our results suggest that a nanoviricide could become a highly sought after drug against HSV.

The market size for herpes simplex virus treatments is in excess of $2 billion annually.

15 comments:

Anonymous said...

Btw.. swine flu outbreak is officially in India now - H1N1 is #1 news on all local tv channels and newspapers.

Anonymous said...

Let the avalanche of good news begin!

Anonymous said...

they had fantastic invitro results for Ebola but dismal results in animal studies!!!!!

Anonymous said...

YAHOO!!!! NNVC Here we Gooooooo!!!

whatisYourRate.com said...

its time for it to hit big..i say $3 a share today!

Allan said...

This is outstanding news, but the real kicker coming for this company will be the announcement of a major deal with big pharma. With so many irons in the fire and the continuing, astounding, and at times stunning news coming out of the lab, it is only a matter of time until we get that deal and announcement. When it hits, you want to be fully invested and since we don't know when it will hit, there is only one strategy with NNVC:

ALL-IN and HOLDING TIGHT

Allan said...

Looks like someone is impressed:

"We've Been Doing Our Research on companies in the NanoMedicine Sector, and we believe that NNVC outshines the rest. We are very pleased to announce NanoViricides (OTCBB: NNVC) ($0.77) as our new stock pick."

http://www.speedtrade.com/

Anonymous said...

Allan, since you picked NNVC as the stock pick for 2009, what do you expect the PPS of NNVC to be at end of 2009??

Allan said...

Re: NNVC price at end of year

No idea, but I'll guess.

If a deal with big pharma happens, north of $5, if not, north of $1.

Dave said...

Yippie Kai Yay!!

Anonymous said...

Re: NNVC price at end of year

THx, Allan.

Burnhard said...

This is awesome news.

But we still have alot to do, this was as cell culture test, now we need animal tests, then human tests... so it might take some time... no idea what the time line will be like... guess we just need to ask about that. Wow..

As for going all in, hmm not me just yet, for now 10% of my port is more then enough (:

Regards,
Bernhard

Anonymous said...

Yep animal studies are the key here. I will be more invested once animal results show tremendous results.

Allan: Are they doing animal studies on the eye formulation? I thought they were starting with this one...

thomas said...

I'm guessing you would agree,from a technical money mgmt.standpoint... that the difference between a full investment now at the $0.90/1.00 area ,while not as good as 67 cents...is still a great bargain, as long as the company doesnt go belly up altogether. For a 50 k investment,all in, we're talking a difference of paying 50 k to buy what 35 k would have got me a few days ago...the difference of 15 thousand dollars,is small change, if this stock gains 500 % or 5 thousand percent..... right?
will it go back down to 30 cents in a year? or 60 cents in a year?.... it sounds like a stock like this, if it does retrace again, you just buy more.
Allan, at this point, based on all your research and analysis about NNVC, how 'risky' is it to invest in this stock? i.e ,the risk of losing everything.... thanks
Thomas

Ubreako said...

Thomas, Please go thru the blog and see how the timeline of the pipeline has played out. THis will help you answer your question.